12. The use according to any one of claims 1 to 11 wherein the effective amount of Treprostinil or a pharmaceutically acceptable salt thereof is at least 1.0 ng/kg of body weight.

13. Method for increasing the cAMP level in a cell in vitro wherein said cell is contacted with at least one prostacyclin or prostacyclin analogue and at least one

PDE4 inhibitor and optionally at least one inhibitor selected from the group of or PDE5 inhibitors, PDE7 inhibitors or PDE8 inhibitors or a pharmaceutically acceptable salt thereof.

14. A therapeutic combination, comprising at least one prostacyclin or prostacyclin analogue and at least one PDE4 inhibitor and ~~optionally~~ at least one inhibitor selected from the group of or PDE5 inhibitors, PDE7 inhibitors or PDE8 inhibitors , wherein the prostacyclin or prostacyclin analogue and PDE4 inhibitor and ~~optionally~~ at least one inhibitor selected from the group of PDE5 inhibitors, PDE7 inhibitors and PDE8 inhibitors are provided in amounts which together are sufficient to treat and/or prevent at least one symptom associated with cystic fibrosis.

15. Therapeutic combination according to claim 14, wherein the prostacyclin or prostacyclin analogue and PDE4 inhibitor and ~~optionally~~ at least one inhibitor selected from the group of PDE5 inhibitors, PDE7 inhibitors and PDE8 inhibitors are formulated for administration by inhalation.

~~16. Use of at least one prostacyclin or prostacyclin analogue and at least one PDE4 inhibitor and optionally at least one inhibitor selected from the group of or PDE5 inhibitors, PDE7 inhibitors or PDE8 inhibitors or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for increasing the cAMP level in a cell.~~